Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Thursday, March 7, 2013

CROI 2013: Dually Active Antiretroviral Therapy Protects Against Primary Hepatitis B Infection

Use of antiretroviral therapy (ART) that includes drugs active against both hepatitis B virus (HBV) and HIV reduces the risk that HIV positive people will become infected with HBV -- in effect acting as HBV PrEP -- according to a study presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this week in Atlanta.


Approximately 6% to 10% of people with HIV are also infected with HBV, and coinfection is associated with more rapid liver disease progression than HBV monoinfection.

Read more...

No comments:

Post a Comment